Humana Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUM research report →
Range $300 – $596
Price Chart
About the company
Humana Inc. , a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services.
- CEO
- James A. Rechtin
- IPO
- 1981
- Employees
- 67,060
- HQ
- Louisville, KY, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a powerful multi-month uptrend and is trading well above its 200-day average, with the 50-day also firmly above the long-term trend. It sits near its 52-week high, signaling a strong secular recovery rather than a late-stage breakdown.
Street sentiment is constructive but not euphoric: the consensus sits at Hold, while the average target of 473.74 is above the last close. Recent changes skew positive, with multiple target raises and upgrades, including Piper Sandler to 526 and Raymond James back to Outperform.
The earnings profile has been resilient, with 7 beats in the last 8 quarters and a 32.0% upside surprise in the latest report. Next-year EPS is modeled at 18.08 versus 10.19 TTM, so shareholders should watch whether margin recovery and utilization trends support that step-up.
Discretionary insider activity leans to net selling, led by a large sale from the Chief Legal Officer and a smaller director sale. The awards and gift entries look like routine compensation or transfers, so the signal is the recent selling rather than the broader transaction count.
Profitability is modest but improving, with a 1.82% operating margin and 26.1% revenue growth year over year. Cash generation is solid at 1.47 billion in free cash flow, but leverage remains meaningful with 12.94 billion of debt against 4.2 billion of cash.
Humana’s managed-care model is supported by scale in Medicare Advantage and CenterWell, but margins remain thinner than higher-quality peers. At 28.37 times earnings, the setup prices in a recovery story rather than a deep value discount.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.83B
- P/E
- 42.72
- Fwd P/E
- 40.89
- PEG
- -14.28
- P/S
- 0.35
- P/B
- 2.83
- EV/EBITDA
- 18.17
- Div Yield
- 0.80%
- Gross Margin
- 13.01%
- Op Margin
- 1.29%
- Net Margin
- 0.81%
- ROE
- 6.70%
- ROIC
- 4.39%
Latest fiscal year · YoY change
- Revenue
- $129.66B+10.1%
- Gross Profit
- $18.85B+9.9%
- Op Income
- $1.45B
- Net Income
- $1.19B-1.6%
- EPS
- $9.87-1.4%
- OCF Growth
- -68.9%
- FCF Growth
- -84.3%
- 52W High
- $462.87
- 52W Low
- $163.11
- 50D MA
- $409.98
- 200D MA
- $321.86
- Beta
- 0.74
- RSI (14)
- 37
- Avg Volume
- 1.44M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Humana said execution is improving, raised full-year EPS guidance, and sees 2027 positioned for margin expansion with a one-time Stars tailwind likely in 2028.· November 6, 2026
- Full-year 2026 adjusted EPS outlook rises to at least $9.50 from at least $9.
- Management said 2027 has no known headwinds beyond this year’s Stars headwind, with several tailwinds from pricing, operations, Medicaid/PCO J-curves, and fewer new members.
- BY ’28 Stars results were described as well above top quartile, with a member-weighted Star rating of 4.17.
- AEP is tracking ahead of initial expectations, with stronger-than-expected retention on exited plans and new sales.
- Balance-sheet actions should improve flexibility, including about $900 million of pretax proceeds from the Gentiva divestiture and a roughly 130 bps GAAP debt-to-cap reduction from the BlackRock JV.
Humana reported third quarter 2026 results and raised its full-year adjusted EPS outlook to at least $9.50 from at least $9. Management said cost trends are in line to better than expectations for both new and existing members, with inpatient favorability and Part D helping drive the higher guidance. For 2027, Celeste Mellet said there are no known incremental headwinds beyond the current Stars headwind and that the company expects material improvement in both Stars-adjusted and Stars-unadjusted earnings, with pricing as the main driver of margin expansion. The company also said its 2027 MA membership is currently expected to be up, though it is too early to quantify precisely.
Jim Rechtin framed the quarter as evidence that Humana’s strategy is working, saying the company is in a good place and moving from on-plan performance toward ahead-of-plan. He emphasized four drivers: product and experience, clinical excellence, efficient operations, and capital allocation, and said the 2027 product portfolio should support the margin progression needed to reach a 3% plus margin in 2028. He also highlighted strong Stars execution, saying the company is operating with more discipline and that the business is now managing toward a top-quartile Stars target rather than top decile.
Celeste Mellet said the company is executing better than initial guidance, with cost trends at the low end of the expected 7% to 8% range this year and the full-year adjusted EPS outlook now at least $9.50. She noted reserves remain prudent, with IBNR up sequentially despite seasonal pharmacy cost mix, and said Humana remains on track to double its individual MA pretax margin this year excluding the Stars headwind. On capital structure, she said the Gentiva minority-interest divestiture should bring about $900 million of pretax proceeds, and the BlackRock JV should reduce GAAP debt-to-cap by about 130 basis points in the fourth quarter while eliminating the need to fund the previously pending 2027 put option.
Analysts pressed management on 2027 MA margin, membership growth, cost trends, PCO pressure, Stars upside, capital deployment, and reinsurance. Management said 2027 should have no new headwinds beyond the current Stars headwind and cited pricing, lower year-one growth costs, and operational transformation as tailwinds, while also saying MA membership is tracking better than feared but remains too early to pin down. On PCO, Celeste said the pressure is concentrated in one geography and should mostly be offset by actions already taken by CenterWell, Humana, and other payers. On capital deployment, management said insurance reserves remain the biggest capital use, while future capital will prioritize Medicaid, CenterWell, dividends, and selective buybacks, though buybacks are debt-to-cap intensive.
The call pointed to stronger execution across multiple fronts: better-than-expected membership, improved product positioning, strong Stars results, and raised earnings guidance. Management sounded increasingly confident that 2027 should show meaningful margin improvement, with 2028 also benefiting from a one-time Stars tailwind and continued operating discipline.
Management still would not quantify 2027 membership or margin precisely, saying AEP retention data is incomplete and that the final level depends on membership mix. Cost pressure is expected to rise next year, especially from the health technology pipeline and Part D, and PCO has seen pressure in one geography tied to certain patients. There is also uncertainty around how much of the 2028 Stars tailwind can be invested versus passed through to earnings.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 120.10M
- Float Shares
- 119.85M
of shares held by institutions
997 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HUM, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Apr 10, 26 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Feb 10, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Aug 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | Nov 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Sep 25, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 5, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 14.26M | ▲ 106.03K |
| Dodge & Cox | 10.94M | ▼ 440.29K |
| Blackrock, Inc. | 10.42M | ▲ 218.75K |
| Vanguard Capital Management LLC | 7.84M | ▲ 4.86K |
| Vanguard Portfolio Management LLC | 5.82M | ▲ 10.52K |
| State Street Corp | 5.54M | ▲ 86.87K |
| Jpmorgan Chase & Co | 3.98M | ▲ 746.56K |
| Eagle Capital Management LLC | 3.85M | ▲ 879.69K |
| Sessa Capital Im, L.P. | 3.73M | 0 |
| Pzena Investment Management LLC | 3.65M | ▼ 753.79K |
| Geode Capital Management, LLC | 3.28M | ▼ 93.25K |
| Massachusetts Financial Services Co | 2.32M | ▼ 1.26M |
Held by 2,140 ETFs
Biggest fund positions in HUM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Frederick Wayne A.I. | sell | 440 |
| Nov 10, 26 | Dintenfass David | other | 230 |
| Nov 9, 26 | Ventura Joseph C | sell | 5,495 |
| Nov 9, 26 | Ventura Joseph C | other | 437 |
| Sep 30, 26 | HILZINGER KURT J | other | 238 |
| Sep 1, 26 | Nundy Shantanu | other | 2,549 |
| Aug 31, 26 | Nundy Shantanu | other | 0 |
| Aug 1, 26 | Smith Paul John | other | 544 |
| Aug 1, 26 | Crawford Frederick John | other | 544 |
| Jul 28, 26 | Crawford Frederick John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HUM coverage
Recent articles, reports, and earnings notes.

Humana (HUM): Medicare Advantage Recovery in Progress
Humana’s Buy case hinges on a rebound in Medicare Advantage economics, improving operating efficiency, and CenterWell growth. The stock still faces meaningful reimbursement, Star Ratings, and medical cost risk.

Humana Inc. (HUM) gains on deep earnings beat analysis
Humana Inc. (HUM) gained after a better-than-feared Q3 earnings beat, but the real story is the deeper recovery setup. Revenue improved sequentially, guidance rose, and management pointed to easing medical cost trends, stronger membership growth, and a clearer path to margin recovery.

Humana Inc. (HUM) gains on earnings beats, up 4.0%
Humana Inc. (HUM) gains 4.0% after reporting earnings beats, lifting shares as investors react to stronger-than-expected quarterly results and improved outlook.
Want a deeper read on HUM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Humana Is Up More Than 50% This Year, but $1,000 From Three Years Ago Is Still Worth Less Than $1,000
247wallst.com · Nov 20
Should Value Investors Buy Humana (HUM) Stock?
zacks.com · Nov 20
Two 68-Year-Old Neighbors With Diabetes Leave Medicare Advantage by Dec. 7. His Plan Is Closing, So Medigap Must Take Him. She’s Leaving by Choice, So a Medigap Insurer Can Turn Her Down
247wallst.com · Nov 19
Humana: The Proposed CRUSH Rule Creates A Buying Opportunity
seekingalpha.com · Nov 19
Humana Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Humana (HUM)
prnewswire.com · Nov 19
UnitedHealth (UNH) vs. Humana (HUM): Buy the Dip?
zacks.com · Nov 17
5 HMO Stocks to Watch Amid Sound Membership Base, Tech Innovation
zacks.com · Nov 17
Humana Inc. (HUM) Hit a 52 Week High, Can the Run Continue?
zacks.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice